🇺🇸 FDA
Patent

US 12234294

Pharmaceutical composition of a humanized anti-CD40 antibody

granted A61KA61K39/39591A61K47/183

Quick answer

US patent 12234294 (Pharmaceutical composition of a humanized anti-CD40 antibody) held by Kiniksa Pharmaceuticals, GmbH expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Kiniksa Pharmaceuticals, GmbH
Grant date
Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K39/39591, A61K47/183, A61K9/0019